title: MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1.
abstract: MicroRNAs (miRNAs) have been identified as important post-transcriptional regulators involved in various biological and pathological processes of cells. In the present study, we investigated the roles and mechanisms of miR-200b in human breast cancer (BC). MiR-200b expression was carried out by qRT-PCR in human BC cell lines and clinical samples and the prognostic potential of miR-200b expression was further evaluated. In vitro, effects of miR-200b on BC cell proliferation, apoptosis and cell cycle distribution were tested by CCK-8 kit, flow cytometric analysis respectively. Luciferase assay and Western blot analysis were performed to validate the potential targets of miR-200b after the preliminary screening by employing open access software. We found that miR-200b was significantly down-regulated in both BC tissues and cell lines. The low expression of miR-200b was correlated with late TNM stage, negative oestrogen receptor and positive HER-2 status. Multivariate analysis showed that miR-200b expression was an independent prognostic predictor for BC patients. Integrated analysis identified Sp1 as a direct and functional target of miR-200b. Knockdown of Sp1 inhibited cell proliferation, induce apoptosis and act on cell cycle resembling that of miR-200b high expression. Our data demonstrates that miR-200b has potential to serve as prognostic biomarker and tumour suppressor for BC patients. As a direct and functional target of miR-200b, Sp1 and miR-200b both could be an exciting target for BC treatment strategy.
authors: Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, China; Molecular Cancer Biology and Translational Medicine Laboratory, Affiliated Hospital of Qingdao University, Qingdao, China.
authors: YaSai
authors: Y
authors: Yao
authors: Jian
authors: J
authors: Hu
authors: Zan
authors: Z
authors: Shen
authors: RuYong
authors: R
authors: Yao
authors: ShiHai
authors: S
authors: Liu
authors: Yong
authors: Y
authors: Li
authors: Hui
authors: H
authors: Cong
authors: XinGang
authors: X
authors: Wang
authors: WenSheng
authors: W
authors: Qiu
authors: Lu
authors: L
authors: Yue
mesh_terms: D020413:3' Untranslated Regions / Q000235:genetics; D017209:Apoptosis / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D061986:MCF-7 Cells; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D034622:RNA Interference; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016329:Sp1 Transcription Factor / Q000235:genetics* / Q000378:metabolism
chemical_list: D020413:3' Untranslated Regions; D014408:Biomarkers, Tumor; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D016329:Sp1 Transcription Factor
keywords: MiR-200b; Sp1; breast cancer; cell growth; prognosis
references: Chin J Cancer. 2011 Aug;30(8):540-50
references: 21801602
references: J Exp Clin Cancer Res. 2010;29:29
references: 20346171
references: Carcinogenesis. 2010 Jan;31(1):100-10
references: 19934210
references: Pharmaceuticals (Basel). 2013 Sep 30;6(10):1195-220
references: 24275848
references: J Neurosci. 1997 Aug 15;17(16):6122-32
references: 9236224
references: Cancer Lett. 2013 Jan 28;328(2):198-206
references: 23022474
references: Mol Cancer Res. 2011 Jan;9(1):25-35
references: 21115742
references: J Biol Chem. 2014 Apr 18;289(16):11194-205
references: 24627491
references: Mol Cancer Ther. 2005 Oct;4(10):1577-84
references: 16227408
references: Endocrinology. 2013 Feb;154(2):635-45
references: 23295740
references: Endocr Relat Cancer. 2011 Feb;18(1):85-95
references: 21051560
references: Oncogene. 2014 Jan 9;33(2):135-47
references: 23455326
references: Breast Cancer Res. 2011;13(2):R24
references: 21375733
references: Ann Surg Oncol. 2014 Mar;21(3):1046-54
references: 24242678
references: Cell Cycle. 2013 Oct 15;12(20):3262-71
references: 24036551
references: Eur J Cancer. 2008 Dec;44(18):2753-9
references: 19022662
references: Nat Cell Biol. 2008 May;10(5):593-601
references: 18376396
references: Pathol Res Pract. 2013 Mar;209(3):179-83
references: 23399321
references: Oncogene. 2006 Oct 9;25(46):6176-87
references: 17028597
references: Mol Cell. 2010 Sep 10;39(5):761-72
references: 20832727
references: Cancer Prev Res (Phila). 2013 May;6(5):401-9
references: 23531448
references: Nucleic Acids Res. 2006;34(8):2294-304
references: 16690972
references: Cancer Biol Ther. 2010 Jul 15;10(2):190-7
references: 20505319
references: Clin Cancer Res. 2013 Oct 15;19(20):5602-12
references: 23995857
references: Cancer Biol Ther. 2010 Aug 1;10(3):219-22
references: 20592490
references: Cell Cycle. 2008 Jun 1;7(11):1529-38
references: 18469525
references: Lancet Oncol. 2013 Dec;14(13):1295-306
references: 24239208
references: Urology. 2010 Sep;76(3):521-7
references: 20472270
references: Oncogene. 2013 Sep 5;32(36):4294-303
references: 23001043
references: Mol Cell Biochem. 2013 Jul;379(1-2):51-8
references: 23543137
references: Mol Neurobiol. 2011 Jun;43(3):215-27
references: 21541853
references: J Urol. 2012 Aug;188(2):615-23
references: 22704449
references: Life Sci. 2008 Aug 29;83(9-10):305-12
references: 18664368